Key takeaways
- Semax and Selank are distinct synthetic peptides with different research backgrounds.
- Gene-expression and animal-behavior results are not direct measurements of human cognitive or anxiety outcomes.
- A nasal-spray label does not prove that a product matches the formulation studied in a paper.
For laboratory research education only. Not medical advice or instructions for human or animal use. RetaSet supplies research materials and publishes this guide; catalog links lead to our own products.
Start with the molecule, not the marketing category
A study examining both peptides in a rat model describes Semax as an analogue of an ACTH fragment and Selank as an analogue of tuftsin. These are different starting points. Grouping the compounds together as “nootropic peptides” does not make their structures, biological effects or evidence interchangeable.
The same caution applies to longer product names. If a listing adds a modification or a salt designation, check whether the cited paper studied that exact material. A familiar root name is not enough to establish equivalence.
For a literature review, write the tested compound’s name exactly as reported before summarizing its findings. That small step makes mismatches between a paper and a product page easier to spot.
Two studies, two different questions
A 2007 Semax study examined neurotrophin gene expression in rat brain and reported changes that depended on the gene and brain region. That finding concerns a molecular measurement in a particular animal experiment.
A 2016 Selank study examined expression of genes involved in neurotransmission in rat frontal cortex, including genes associated with GABA-related signaling. The researchers assessed a defined set of genes at specified times. This provides a research observation to investigate further, not a direct reading of how a person would feel.
These papers are useful examples of how the evidence differs; this table is not an exhaustive review or a head-to-head efficacy comparison.
| Paper | What was measured | What the result does not establish |
|---|---|---|
| Semax, 2007 | Neurotrophin gene expression in rat brain | A demonstrated improvement in human memory |
| Selank, 2016 | Neurotransmission-related gene expression in rat frontal cortex | A proven human anxiety treatment or a known direct receptor mechanism |
Why a gene-expression change is not a benefit score
When a paper reports a change in gene expression, it is tempting to translate the result into a simpler phrase such as “better focus.” That translation introduces a new claim. The measurement and the everyday description do not refer to the same endpoint.
Consider a hypothetical research summary: “Expression of a named gene changed in this brain region at this observation time.” A careful summary preserves those boundaries. Rewriting it as “the peptide improves cognition” removes the model, timing and measurement while adding an outcome that the sentence has not demonstrated.
For a fair Semax vs Selank comparison, put the studies side by side only after matching the questions they ask. Differences between species, experimental conditions and endpoints can be more consequential than the shared word peptide. Where the studies do not match, say so instead of declaring a winner.
What does a Semax or Selank nasal-spray listing tell you?
Searches such as “what is Semax spray” and “what is Selank nasal spray” describe a marketed presentation. The words alone do not establish the identity, formulation, quality or regulatory status of the contents.
If a paper used an intranasal route, that still does not demonstrate that a separately sold spray reproduces the experiment. The formulation and tested material matter, as do the species and the measured endpoint. A route name is one item in the methods, not a bridge from an animal finding to a personal-use recommendation.
Our linked catalog pages are research-material listings. They should not be read as evidence that a nasal product is offered or that a laboratory material is suitable for administration. This article contains no dosing or preparation instructions.
Safety uncertainty belongs in the comparison
As checked on 28 September 2026, the FDA’s compounding safety page includes Selank acetate and Semax in its section for substances nominated but withdrawn. It describes potential immunogenicity concerns associated with aggregation and peptide-related impurities, and gaps in safety information.
That is a specific U.S. compounding context. It should not be rewritten as a worldwide regulatory determination. It also should not be omitted from a comparison merely because an earlier experimental result sounds promising.
The practical reading rule is to keep benefit hypotheses and safety knowledge separate. An interesting biological signal does not fill a missing safety dataset.
A comparison worksheet that stays honest
For each paper, record the exact compound, model, comparator, measured endpoint, observation period and the authors’ stated limitations. Then add a final column: “What would need to be shown next?” That last question prevents a preliminary observation from becoming a settled conclusion in your notes.
For laboratory procurement, make a separate record for the supplied lot and its analytical documentation. Literature on a named peptide does not test the vial you receive. Use the catalog and available certificates to establish what documentation exists, and request clarification where the identity or intended specification is unclear.
A useful comparison does not need a winner. It needs a clear account of which questions the evidence answers and which remain open.
Common questions
Are Semax and Selank the same peptide?
No. They are distinct synthetic peptides with different research backgrounds. A shared marketing category does not make them equivalent.
Do the cited studies prove benefits from a Semax or Selank nasal spray?
No. The studies discussed here measure specific outcomes in rats. They do not establish benefits or safety for a separately marketed nasal spray in humans.
Can findings about an unmodified peptide be applied to an acetylated version?
Do not assume so. Check the exact material used in the study and the evidence for the modified compound rather than treating similar names as proof of equivalence.
Explore research materials
Explore the Research Peptide Catalog for Semax and Selank laboratory-material specifications. Review the exact identity and lot documentation; these links are not recommendations for human use.
Product links support research procurement only. Availability and specifications can change. Contact RetaSet for missing product documentation. Read the shipping policy.
